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Living at Altitude Adversely Affects Survival
Among Patients With a Fontan Procedure
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Objectives This study sought to determine whether survival in this cohort of patients was adversely affected by increased
residential altitude.
Background The success of the Fontan procedure depends in large part on low pulmonary vascular resistance (PVR). Factors
that increase PVR, including an increase in residential altitude, may adversely affect long-term outcome. Higher
altitude has been shown to affect functional well-being in patients with a Fontan circulation.
Methods Databases from a tertiary cardiac care center in the Intermountain West (elevation 5,000 feet) were analyzed
for patients born with single-ventricle anatomy who would now be of adult age. Complete data were then col-
lected on all identified patients who subsequently underwent the Fontan operation. Correlates of, and time to,
adverse outcome, defined as death, cardiac transplantation, or clinical decompensation requiring a move to sea
level, were determined.
Results Of 149 patients with single-ventricle anatomy, 103 underwent the Fontan procedure, with 70 surviving to adult-
hood at moderate altitude. Adverse outcome occurred in 55, with death in 24 (23%), cardiac transplantation in
18 (17%), and clinical decompensation requiring move to sea level in 13 (13%). There was no relationship be-
tween type, age at, or era of Fontan procedure and long-term outcome. Correlates of long-term, transplant-free
survival at moderate altitude included lower residential altitude (4,296 vs. 4,637 feet, p  0.001), and lower
pulmonary artery pressures before the Fontan procedure (13 vs. 15 mm Hg, p  0.01), and after (14 vs.
18 mm Hg, p  0.01).
Conclusions Long-term outcome after the Fontan procedure is adversely impacted by higher residential altitude. (J Am Coll
Cardiol 2013;61:1283–9) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.008a
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WThe Fontan procedure is the anticipated final surgical
intervention in children with single-ventricle anatomy. The
procedure, first described by Dr. Fontan in 1971, revolu-
tionized the outlook of patients with single-ventricle anat-
omy as it allowed them to survive into adulthood. The
surgical procedure requires rerouting of superior and inferior
caval flow to the pulmonary arteries without an intervening
pump, and thus, low pulmonary vascular resistance is critical
to the success of the procedure (1).
With increased elevation, there is a reduction in the
partial pressure of oxygen (pO2), which serves as the
timulus for a number of physiological changes including an
ncrease in plasma catecholamines and renin activity, result-
ng in an increase in systemic and pulmonary vascular
esistance, as well as heart rate (2). These physiological
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2012, accepted January 3, 2013.daptations may prove particularly detrimental to the pa-
ient who has undergone Fontan palliation. The negative
mpact of increased altitude on early Fontan hemodynamics
as been described (3), as has acute clinical deterioration of
ea level residents with a Fontan circulation who have been
xposed to moderate altitude (4,5). The long-term outcome
f patients residing at moderate altitude after the Fontan
rocedure, however, is unknown. We sought to assess
orbidity and mortality in a group of patients with a Fontan
irculation followed up at a tertiary center located at
oderate altitude and to determine what, if any, effect
esidential elevation has had on long-term survival.
ethods
n institutional review board–approved retrospective review
f surgical, cardiac catheterization, and clinical databases
rom a tertiary cardiac care center located at an elevation of
,000 feet and serving a 3-state region in the Intermountain
est was performed. Patients with single-ventricle anat-my who would now be of adult age (18 years) were
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tial review were then included in
the study for further analysis if
they had undergone a Fontan
operation.
Records were reviewed, and
the following demographic and
surgical variables were recorded:
date of birth, sex, date of Fontan
procedure, type of initial Fontan
procedure (atriopulmonary, lat-
eral tunnel, or extracardiac conduit), presence or absence of
surgical fenestration, presence or absence of prior cavopulmonary
anastomosis, interval between cavopulmonary anastomosis and
subsequent Fontan procedure, presence and date of surgical
conversion to an alternate type of Fontan, and need for
surgical revision of the primary Fontan connection. Pres-
ence and absence of a pacemaker was noted. Cardiology
variables including systemic ventricular morphology (right,
left, or indeterminate), pulmonary artery (PA) pressures on
pre-Fontan cardiac catheterization, subsequent percutane-
ous or spontaneous fenestration closure, and PA pressures at
cardiac catheterization at last follow-up were noted.
The following outcomes were noted to be present or
absent: protein-losing enteropathy (PLE) defined by an
elevated stool alpha-1 antitrypsin and associated hypoalbu-
minemia, plastic bronchitis, thrombosis defined as a clini-
cally symptomatic thromboembolic event, death, listing for
cardiac transplantation, and clinical decompensation
prompting relocation to lower altitude. New York Heart
Association (NYHA) classification and oxygen saturations
at rest and with exercise were recorded at last follow-up
before death, transplantation, or move from moderate alti-
tude to sea level. For the purposes of this study, moderate
altitude was defined as 3,000 feet elevation (4).
Subjects were categorized as: 1) those with composite
adverse outcome; and 2) those without composite adverse
outcome, defined as death, cardiac transplantation or listing
for cardiac transplantation, or move to sea level for cardiac
decompensation. Adverse outcomes of death and cardiac
transplantation were also analyzed individually. Date of
composite adverse outcome and cause of composite adverse
outcome were recorded. Cause of adverse outcome was
identified as heart failure, Fontan failure, thrombosis, PLE,
hepatic dysfunction, sudden death, perioperative death, or
other. Heart failure was defined as NYHA class III or
greater symptoms in the face of qualitatively impaired
systemic ventricular function on echocardiogram. Fontan
failure was defined as NYHA class III or greater symptoms
in the face of qualitatively normal systemic ventricular
function on echocardiogram and elevated PA pressures on
cardiac catheterization. Hepatic dysfunction was defined as
functional abnormalities noted on serology in association
with structural alterations present on liver biopsy. Sudden
death was defined as death within 3 h of the onset of
Abbreviations
and Acronyms
BDCPS  bidirectional
cavopulmonary shunt
NYHA  New York Heart
Association
PA  pulmonary artery
PLE  protein-losing
enteropathysymptoms and perioperative death was defined as deathwithin 28 days of cardiac surgery. The “other” category
included patients who died of noncardiac reasons or patients
for whom the cause of death could not be elucidated.
Residential elevation was determined by using an ad-
justed average of the elevation of the zip codes at which the
patient resided between the Fontan operation and the
clinical endpoint (death, cardiac transplantation, move to
sea level, last visit).
Patients were classified by initial Fontan type defined as
atriopulmonary connection, lateral tunnel type, or extracardiac
conduit, depending on the surgical procedure performed.
Repeat analyses using final Fontan type was also performed to
assess for clinical effect in patients undergoing conversion from
one type of Fontan to another.
All patients were followed up in either a pediatric
cardiology or an adult congenital cardiology academic prac-
tice. Patients were seen with the frequency that their clinical
condition demanded, with recommended follow-up at least
annually. Echocardiograms were obtained at the discretion
of the patients’ primary cardiologist but were performed at
least annually. Patients with symptoms of heart failure or
functional deterioration underwent cardiac catheterization.
If the source of heart failure was myocardial dysfunction,
heart transplant work-up was considered and discussed with
the patient. In light of prior publications noting an almost
universal decline in functional status of sea level Fontan
patients traveling to moderate altitude (4), patients with
preserved myocardial function but elevated PA pressures
were given a trial of oxygen and medical therapies for
pulmonary hypertension. If they continued to have incapac-
itating symptoms of heart failure, or persistent symptomatic
desaturation, and if they had noted improvement in these
symptoms at lower elevations, a move to sea level was
discussed. For patients unwilling or unable to relocate,
cardiac transplantation was discussed. Patients were listed
for cardiac transplantation at the discretion of the heart
failure/transplant team at our center. Medications, includ-
ing anticoagulants, were prescribed at the discretion of the
patient’s primary cardiologist and were not standardized
across providers. All patients were treated with either aspirin
or warfarin for anticoagulation therapy. All patients with
prior thromboembolic events or sustained atrial arrhythmias
were managed on warfarin.
Statistical analysis. Statistical analysis was conducted us-
ing SAS version 9.2 (SAS Institute, Cary, North Carolina).
Continuous data were expressed as means with standard
deviations or medians with ranges as appropriate, and
categorical data were tabulated. A 2-sided p value of  0.05
was considered statistically significant. Demographic and
clinical data for adult survivors with adverse outcome, and
survivors without an adverse outcome were compared using
a chi-square test, for dichotomous or categorical variables,
and a Student t test or Wilcoxon rank-sum test for contin-
uous variables depending on their normality. Patient data
were censored on the basis of their last known visit if they
were lost to follow-up. Kaplan-Meier survival curves were
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well as time to death or transplantation alone. Correlates of
the presence of, and time to, composite adverse outcome
were sought initially on univariate analyses. Multivariate
analyses with Cox proportional hazards regression were
performed to estimate hazard of the outcome. Factors that
had a p value 0.2 were included in the model to determine
the adjusted odds ratio. Variables were retained if they
changed the point estimate by 10%.
Results
Of 149 patients born between 1965 and 1991 with single-
ventricle physiology, 103 underwent a Fontan procedure
during the period 1978 to 2005; the remainder either died
or were not considered to have hemodynamics suitable for a
Fontan procedure and underwent palliation with a bidirec-
tional cavopulmonary anastomosis alone or cardiac trans-
plantation. Of those undergoing the Fontan procedure, 70
patients (68%) survived into adulthood at moderate altitude
without heart transplantation, with a median age of these
survivors of 29.2 (18.1 to 40.4) years.
Outcomes of the Fontan cohort are depicted in Figure 1.
Of the initial 103 patients, 24 (23%) died at a median age of
13.5 (0.5 to 36.9) years. An additional 18 patients were
listed for cardiac transplantation at a median age of 18.2 (3.5
to 40.8) years. Thirteen (13%) additional patients moved to
sea level due to cardiac decompensation at a median age of
16.5 (8.2 to 28.8) years, and 3 moved out of state, to lower
altitude, for noncardiac reasons, leaving 45 patients (43%) from
the initial Fontan cohort currently alive as adults at moderate
altitude without listing for cardiac transplantation. Within this
group of survivors, oxygen saturations were 89.0 3.5% at rest
and fell to 84.6  5.1% with exercise.
Cause of composite adverse outcome. Cause of adverse
outcome is listed in Figure 1. There was significant overlap
Figure 1 Overview of Study Population
PLE  protein-losing enteropathy. *Alive refers to transplant-free survival at altiudof comorbidities, with many patients having 1 (Table 1).Of 85 patients surviving into adolescence, 41 (48%) had a
clinically significant thrombotic event (stroke, pulmonary
embolus, renal artery thrombosis, or coronary artery throm-
boembolus with myocardial infarction). Twenty-six (44%)
of the 59 patients who underwent hepatic evaluation were
found to have physiologic or anatomic hepatic abnormali-
ties. Protein-losing enteropathy was diagnosed in 19 (27%)
of the 71 patients who underwent evaluation for such.
Transplant-free long-term survival was quite low among
patients with PLE, with only 3 of 19 (15%) still alive. Of the
3 survivors, 1 is being evaluated for heart and liver trans-
plantation, 1 is in hospice care, and the other remains stable
with a recurrent relapsing course on medical therapy. All
nonsurviving patients with PLE died of fatal thrombotic
events.
Correlates of adverse outcome. Initial Fontan procedure
was an atriopulmonary connection in 54 patients (52%),
lateral tunnel in 36 (35%), and extracardiac conduit in 13
(13%). Hemodynamic and anatomic variables categorized
by type of initial Fontan surgery are displayed in Table 2. As
in many centers in North America, our center underwent a
surgical revolution throughout the years, transitioning from
the initial atriopulmonary connection, to the lateral tunnel,
and subsequently to the extracardiac conduit. Concomitant
with this transition was a trend toward performing a
Morbidities in the Fontan Cohort (n  103)Table 1 Morbidities in the Fontan Cohort (n  103)
Adverse Outcome n (%)
PLE* 19 (26.7)
Thrombosis† 41 (48.8)
Heart failure‡ 22 (37.9)
Hepatic dysfunction§ 26 (44.1)
Fontan failure 20 (22.2)
*n  71 with evaluation; †n  85 surviving into adolescence; ‡n  58 with evaluation; §n  59e.with evaluation; n  90 with evaluation.
PLE  protein-losing enteropathy.
onary s
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This is reflected in Table 2 as a significant difference in the
presence of a cavopulmonary anastomosis between the
different types of Fontan procedure. Another historical
trend that occurred during the study period was the practice
of palliating infants with hypoplastic left heart variants.
This, too, is reflected in Table 2 as patients undergoing a
more modern version of the Fontan procedure were more
apt to have a systemic right, rather than left, ventricle.
Demographic and clinical variables for patients with and
without composite adverse outcome are depicted in Table 3.
Underlying ventricular morphology, age, and type of surgery
did not correlate with long-term outcome. The initial
presence and persistence of a patent fenestration was not
correlated with adverse outcome. Fourteen patients under-
went Fontan conversion; 12 patients had conversion to an
extracardiac Fontan, 9 from an atriopulmonary connection
and 3 from a lateral tunnel. Two patients were converted
from an atriopulmonary connection to a lateral tunnel
Fontan. Four additional patients underwent 6 revisions
without subsequent conversion, 3 had revision of an atrio-
Baseline Characteristics by Type of Initial FontaTable 2 Baseline Characteristics by Type of
Characteristics Total (n  103)* A
Male 55 (53.4%)
Age at Fontan, yrs 5.7 (0.5–22) 6
Systemic ventricle
Right ventricle 35 (33.9%)
Left ventricle 68 (66.1%)
Prior BDCPS 46 (44.7%)
Pre-Fontan mean PAP, mm Hg 14 (6–27)
Follow-up after Fontan, yrs 15.7 (0–29.1) 18
Values are n (%) or mean (range). *One patient with unknown type ex
APC atriopulmonary connection; BDCPS bidirectional cavopulm
PAP  pulmonary artery pressure.
Demographic and Clinical DataTable 3 Demographic and Clinical Data
Demographics
Adverse
Outcome (n  54)
No Adverse
Outcome (n  44) p Value
Male 30 (55.6%) 24 (54.5%) 0.92
Age at Fontan, yrs 7.15 (0.5–22.0) 5 (1.2–16.0) 0.33
Age at last follow-up, yrs 28.9 (0.5–40.8) 25.7 (16.9–40.3) 0.52
Systemic ventricle 0.33
Left ventricle 38 (70.4%) 25 (56.8%)
Right ventricle 16 (29.6%) 19 (43.2%)
Initial Fontan type 0.48
Atriopulmonary
connection
30 (55.6%) 21 (47.7%)
Lateral tunnel 15 (27.8%) 18 (40.9%)
Extracardiac conduit 8 (14.8%) 5 (11.4%)
Surgical fenestration 22 (40.7%) 19 (43.2%) 0.93
Closure of fenestration* 8 (14.8%) 10 (22.7%) 0.43
Fontan revision 10 (18.5%) 8 (18.1%) 0.59
BDCPS before Fontan 20 (37%) 26 (59.1%) 0.03
Presence of pacemaker 23 (42.6%) 15 (34.1%) 0.002Values are n (%) or mean (range). *Refers to closure by cardiac catheterization.
BDCPS  bidirectional cavopulmonary shunt.
fpulmonary connection and 1 a lateral tunnel revision. One
of these 4 patients underwent 3 revisions of an atriopulmo-
nary Fontan, with intraoperative death during the third
revision. Patients having undergone Fontan conversion were
equally likely to have a long-term adverse outcome (Table 3).
Age at last follow-up did not differ between those with
versus without adverse outcomes (28.9 [0.5 to 40.8] vs. 25.7
[16.9 to 40.3]; p  0.52).
Nonsurgical variables associated with long-term compos-
ite adverse outcome were initially explored with univariate
analyses and included residential elevation, pre-Fontan
mean PA pressures at cardiac catheterization, post-Fontan
mean PA pressures at most recent cardiac catheterization,
resting oxygen saturation, presence of PLE, presence of
hepatic dysfunction, age at Fontan, type of initial Fontan, or
age at last follow-up (Table 4). Factors associated with
adverse outcome on univariate analysis also included the
presence of a pacemaker, and lack of a bidirectional cavo-
pulmonary anastomosis before Fontan surgery. However,
when adjusted for era of surgery as defined by 1970 to the
1980s versus 1990 to the 2000s in multivariate analysis, the
presence of a bidirectional cavopulmonary anastomosis no
longer correlated with outcome (Table 5).
Cox proportional hazard regression modeling was used to
estimate the hazard ratio of a composite adverse outcome.
Thrombosis, PLE, residential elevation, pre-Fontan PA
pressure, recent post-Fontan PA pressure, and resting O2
saturation were adjusted for in multivariate analysis. In
rgeryal Fontan Surgery
 54) LTF (n  36) ECF (n  12) p Value
.8%) 22 (61.1%) 6 (50.0%) 0.46
–16.7) 4.8 (1.2–15.4) 7.5 (4.6–22.0) 0.03
.7%) 19 (52.8%) 7 (58.3%) 0.001
.3%) 17 (47.2%) 5 (41.7%)
.9%) 21 (58.3%) 10 (83.3%) 0.001
27) 14 (8–25) 12 (10–19) 0.39
29.1) 17.4 (2.1–26.7) 7.5 (0.5–13.1) 0.002
from comparative analysis.
hunt; ECF extracardiac conduit Fontan; LTF lateral tunnel Fontan
Correlates of Adverse OutcomeTable 4 Correlates of Adverse Outcome
Correlates of Outcome
Adverse
Outcome
(n  54)
No Adverse
Outcome
(n  44) p Value
Residential elevation, ft 4,637 (4,462–4,900) 4,296 (4,260–4,512) 0.001
Hepatic dysfunction* 10 (18.5%) 16 (36.4%) 0.68
Thrombosis 22 (40.7%) 16 (36.4%) 0.03
PLE† 15 (27.8%) 4 (9.1%) 0.001
Resting O2 saturation 89 (84–92) 91 (88–93) 0.06
Pre-Fontan PAP, mm Hg 15 (13–18) 13 (10.5–15) 0.02
Post-Fontan PAP, mm Hg 18 (12–20) 14 (13–17) 0.25
Values are mean (range) or n (%). *n  59 evaluated for hepatic dysfunction; †n  71 evaluatedn SuIniti
PC (n
28 (51
.7 (0.5
9 (16
46 (83
14 (25
14 (6–
.4 (0–
cludedor protein-losing enteropathy (PLE).
PAP  pulmonary artery pressure.
d
f
2
h
d
w
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analysis and hazard ratio determination; and the bottom
part shows the Cox proportional hazard regression mod-
eling estimating the hazard ratio of presence of a bidi-
rectional cavopulmonary anastomosis before Fontan and
is adjusted for residential elevation and era of surgery,
with only residential elevation showing a statistically
significant association.
Figure 2 demonstrates the cumulative survival, and free-
om from death, transplant, or move to sea level. Freedom
rom death, transplant, or move to sea level at 5, 10, 15, and
0 years was 84.7%, 67.3%, 55.1%, and 26.5%, respectively.
In analysis of outcome as death or transplant, 93 patients
ad data for analysis. Forty-six (49.5%) had an outcome of
eath or transplant, which was not significantly associated
ith sex, presence of hepatic dysfunction, age at last
Cox Proportional Hazards Regression ModelTable 5 Cox Proportional Hazards Regressio
Hazard Ra
Covariates*
Residential elevation, per 100 ft 1.084
Resting O2 saturation, per 1% 0.866
Pre-Fontan PAP, per 1 mm Hg 1.215
Thrombosis 3.628
Protein-losing enteropathy 7.002
Covariates†
Residential elevation, per 100 ft 1.087
1986–1990 vs. 1978–1985 1.206
1991–1995 vs. 1978–1985 1.168
1996–2002 vs. 1978–1985 2.717
BDCPS before Fontan 0.592
*Results of the multivariate analysis and hazard ratio determination.
presence of a bidirectional cavopulmonary anastomosis before Fonta
Abbreviations as in Table 2.
Figure 2 Overall Kaplan-Meier Survival Curve
A total number of 98 patients was used. Censoring occurs at the time of last
known follow-up. Total number of censored patients was 44 (44.90%).follow-up, age at Fontan, type of Fontan, or presence of
surgical fenestration. A summary of significant associations
can be seen in Table 6. Era of surgery was also analyzed by
a Cox proportional regression model. There was a hazard
ratio of 0.998 with a confidence interval of 0.552 to 1.802,
and a p value of 0.99 when composite adverse outcome was
analyzed by surgical era divided into 1970 to 1980 and 1990
to the 2000s.
When analyzed for freedom from transplant or death,
freedom from death or transplant at 5, 10, 15, and 20 years
was 84.9%, 69.9%, 57%, and 25.8%, respectively. Figure 3
shows the Kaplan-Meier survival curve for freedom from
death or transplant.
Discussion
As patients with the Fontan procedure have entered into
adulthood, the long-term complications of this passive
circulation have become evident. Despite this, the Fontan
procedure remains the definitive surgical intervention of
choice for patients with single-ventricle anatomy at most
del
95% Hazard Ratio
Confidence Interval p Value
1.03 1.14 0.002
0.766 0.979 0.02
1.018 1.452 0.03
1.128 11.668 0.03
2.288 21.425 0.001
1.03 1.14 0.002
0.56 2.6 0.63
0.50 2.7 0.72
0.85 8.7 0.09
0.31 1.2 0.11
oportional hazard regression modeling estimating the hazard ratio of
Correlates of Outcome ofDeath or Cardiac TransplantationTable 6 Correlates Outc me ofDeath or Cardiac Transplantation
Correlates of Outcome
Death or
Transplant
(n  46)
No Death or
Transplant
(n  47) p Value
Thrombosis 20 (43.4%) 17 (36.2%) 0.026
Protein-losing enteropathy 15 (32.6%) 4 (8.5%) 0.001
Had BDCPS before Fontan 16 (34.7%) 27 (57.4%) 0.03
Elevation, ft, median 4,637 (1,490–5,948) 4,296 (43–5,547) 0.001
Pre-Fontan PAP, mm Hg,
median
15 (9–27) 13 (6–27) 0.01
Most recent Fontan pressure,
mm Hg, median
18 (9–28) 14 (7–22) 0.01
Resting O2 saturation, %,
median
88 (7–98) 91 (78–96) 0.01n Mo
tio
†Cox prValues are n (%) or median (range).
Abbreviations as in Table 2.
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erate altitude. To date, there are minimal data on actuarial
survival and clinical complications of the Fontan procedure
in patients residing at moderate altitude. This study pro-
vides an analysis of long-term follow-up and presence of
comorbidities for a cohort of patients who are, or would
have been, of adult age with single-ventricle physiology
palliated with a Fontan procedure at moderate altitude.
When compared to previously published studies on sea
level Fontan patient cohorts, our study demonstrates mark-
edly reduced transplant-free survival. Khairy et al. (6)
documented 15-year and 20-year survival of 72% and 65%,
respectively, in a sea level cohort, in contrast to our survival
rates of 57% and 25%. The reduction in survival is not
particularly surprising if one considers the physiological
adaptations to increased elevation present at moderate
altitude. The rise in pulmonary vascular resistance will lead
to impedance to forward flow through the Fontan circuit,
predisposing to Fontan failure, hepatic congestion, and PLE.
It is, therefore, not surprising that the incidence of PLE in our
patient cohort was more than double that previously reported
among patients living at low elevation (7–9). Our finding of
impaired survival in patients with PLE is consistent with
previously published reports (6,8). Patients with a persistent
fenestration may be spared from such gastrointestinal and
hepatic complications but will have erythrocytosis in asso-
ciation with their increased cyanosis, thus potentially pre-
disposing them to thromboembolic complications. Increas-
ing elevation further increases hematocrit, which may be
particularly disadvantageous to these patients. Even in the
absence of a patent fenestration, desaturation was almost
universal in our patient cohort, and the risk of thrombosis
was significantly higher than previously reported estimates
of 21% to 25% in low-altitude patients (10–12). Although
Figure 3 Freedom From Death or Transplant
There was a total of 93 patients available for analysis. Total number of cen-
sored patients was 47 (50.54%).all patients with a documented thromboembolic event wereplaced on a regimen of warfarin, the clinical benefit of
warfarin versus aspirin therapy for primary prophylaxis of
thrombus formation in this patient population remains
unknown. In a review of the available literature in 2002, it
was considered that there was insufficient evidence to make
recommendations regarding thromboembolic prophylaxis
for this population (13). Given the very high rate of
thromboembolism in our patient cohort, however, consid-
eration may need to be given to a multicenter study of
primary thromboprophylaxis of Fontan patients living at
moderate or greater altitude. The higher baseline incidence
may allow for better ascertainment of clinical effect.
The increase in systemic vascular resistance that occurs at
increasing elevations may adversely affect systemic ventric-
ular function, atrioventricular valve regurgitation, and sys-
temic ventricular filling, thereby predisposing patients to
both myocardial dysfunction and Fontan failure, which were
also common among our adult patients. The altitude-related
increase in catecholamines may further predispose to ar-
rhythmias, which may in turn be associated with thrombo-
sis, and myocardial dysfunction. Given these changes in
physiology, the population of Fontan survivors at moderate
altitude may respond to medical therapies differently than
their counterparts at sea level. Higher renin levels (2) and
reduced inhaled nitric oxide responsiveness (14) may affect
the impact of therapies such as angiotensin-converting
enzyme inhibitors and phosphodiesterase-5 inhibitors in
patients living at moderate altitude.
Our findings are consistent with those of other investi-
gators assessing early post-operative outcome and functional
status. In their review, Hosseinpour et al. (3) described
increased early Fontan failure, defined as death, Fontan
takedown, or cardiac transplantation, at higher elevations
ranging up to 520 m (approximately 1,700 feet). Impaired
growth (15) and reduced exercise tolerance (16) have also
been noted in this patient cohort when compared to sea
level controls. The Pediatric Heart Network investigators
recently reported on the functional status of patients with a
Fontan circulation (17), and noted greater impairment in
functional status and decreased ventricular systolic function
in patients with a pacemaker. Similarly, patients with a
pacemaker were more likely to experience an adverse clinical
outcome in our series.
It is not known, what, if any, absolute residential eleva-
tion is not detrimental to the Fontan patient. We have
demonstrated on multivariate analysis that, with an altitude
median of 4,500 feet (interquartile range: 4,260 to 4,699
feet), the risk of an adverse event appears to linearly increase
with increasing residential altitude. Similarly, Darst et al.
(16) demonstrated a continuous effect of increasing eleva-
tion on exercise performance with a linear decline in exercise
performance over a range of elevations from sea level to
those in excess of 6,000 feet in a large cohort of Fontan
patients.
Study limitations. This study was retrospective in nature
and thus limited to the data collected as part of routine
1289JACC Vol. 61, No. 12, 2013 Johnson et al.
March 26, 2013:1283–9 Fontan Survival at Altitudeclinical care. As such, the date of onset of each adverse event
cannot be defined, but rather, only the date of diagnosis of
the adverse event. However, the timing of the composite
adverse outcomes was precisely known. Although in any
retrospective study the potential for uncontrolled confound-
ing exists, the primary clinical confounders such as PA
pressures, other adverse events such as thrombosis, PLE or
hepatic complications, as well as era of surgery, were
controlled for. However, there remains the possibility of
uncontrolled confounding as retrospectively immeasurable
factors such as income, socioeconomic status, and access to
healthcare could be associated with both residential eleva-
tion and outcome. As there was a significant span of years
over which the Fontan procedure was performed, there is
potentially an era effect, with patients in the earlier era
having worse outcomes. However, there was no statistical
difference in the number of adverse outcomes when adjusted
by surgical era. Our composite adverse outcome included
patients moving to lower elevation for relief of symptoms.
The effect of relocation in these subjects is unknown,
however. Therefore, the data were analyzed with 2 different
definitions of composite adverse outcome, the one including
these patients and the other limited to death or cardiac
transplantation.
Conclusions
Patients with a Fontan circulation residing at moderate
altitude have decreased rates of transplant-free survival. We
have identified risk factors for adverse outcome in this group
of patients, including higher PA pressures, lower oxygen
saturations, presence of thrombosis or PLE, and increased
residential elevation. The effect of relocation to lower
elevation remains unknown but is deserving of future study.
Presence of these other risk factors should prompt consid-
eration of transplantation or a trial of living at sea level.
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